03.11.20: Q3 2020 Investor Conference Call
Q3 2020 Investor Conference CallLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 20, 2020 Category: Pharmaceuticals Source Type: news
19.10.20: Start of Quiet Period
Start of Quiet PeriodLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 18, 2020 Category: Pharmaceuticals Source Type: news
14.10.20: Not intended for U.S. and UK Media
Combination of copanlisib and rituximab significantly prolonged progression-free survival of patients with relapsed indolent non-Hodgkin's LymphomaPhase III study CHRONOS-3 in patients with relapsed indolent non-Hodgkin's Lymphoma (iNHL) who have received one or more lines of prior treatment meets primary endpoint / Safety and tolerability observed in the trial were generally consistent with previously published data on the individual components of the combination and no new safety signals were identified / Copanlisib is already approved in the U.S. under accelerated approval based on overall response rate (ORR) of 104 adu...
Source: Bayer IR Newsfeed: Events - October 14, 2020 Category: Pharmaceuticals Source Type: news
12.10.20: Not intended for U.S. and UK Media - American Society of Nephrology (ASN)'s Kidney Week 2020 Reimagined:
Finerenone Phase III FIDELIO-DKD study in chronic kidney disease and type 2 diabetes to be presented as late-breaking clinical trial at ASN 2020FIDELIO-DKD is the first large contemporary positive outcomes study in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) with a primary composite endpoint consisting exclusively of kidney-specific outcomes / Finerenone, a first-in-class investigational non-steroidal, selective mineralocorticoid receptor (MR) antagonist, demonstrated positive renal and cardiovascular outcomes in patients with CKD and T2D / Preclinical data on finerenone, as well as a range of post...
Source: Bayer IR Newsfeed: Events - October 13, 2020 Category: Pharmaceuticals Source Type: news
30.09.20: Bayer to accelerate transformation to address challenging market environment and enable additional growth investments
Bayer to accelerate transformation to address challenging market environment and enable additional growth investmentsAdjusted outlook for 2020 confirmed / 2021 sales expected at approximately 2020 levels despite significant headwinds from COVID-19 pandemic; 2021 core earnings per share expected to be slightly below 2020 levels at constant exchange rates / Lower than expected outlook in the agricultural market likely to lead to mid-to-high single-digit billion-euro non-cash impairment charges in the Crop Science business / Strengthening margin profile and funding of additional investments in innovation and growth through ad...
Source: Bayer IR Newsfeed: Events - October 1, 2020 Category: Pharmaceuticals Source Type: news
28.09.20: Not intended for U.S. and UK Media
Bayer's XtendFlex Soybeans Gain Final Key Regulatory ApprovalEuropean Commission's Green Light Enables a Full Launch in 2021mehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - September 29, 2020 Category: Pharmaceuticals Source Type: news
17.09.20: ESMO Virtual Congress 2020:
New data reinforce strong clinical profile of Vitrakvi™ for patients of all ages with TRK Fusion Cancer including lung and thyroid tumors78% overall response rate (ORR) and median progression-free survival (PFS) of more than 3 years (36.8 months) demonstrate extended benefit in updated data set of 175 adults and children / Majority of adverse events were grade 1 or 2; no new safety signals identified / Consistently high ORRs shown in lung and thyroid data subsets (71 and 75%, respectively) as well as long durability (estimated duration of response at 12 months of 88% and 95%, respectively) / Among patients from integ...
Source: Bayer IR Newsfeed: Events - September 17, 2020 Category: Pharmaceuticals Source Type: news
15.09.20: Not intended for U.S. and UK Media
Bayer and Systems Oncology sign exclusive license agreement on innovative breast cancer treatment approach ERSO™ mehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - September 16, 2020 Category: Pharmaceuticals Source Type: news
10.09.20: Bayer: Supervisory Board extends CEO Werner Baumann's contract until the end of April 2024
Bayer: Supervisory Board extends CEO Werner Baumann's contract until the end of April 2024Company also announces progress in Roundup™ settlementsmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - September 11, 2020 Category: Pharmaceuticals Source Type: news
09.09.20: Not intended for U.S. and UK Media
New England Journal of Medicine publishes final overall survival data for Nubeqa™ (darolutamide) showing treatment significantly extends life in men with non-metastatic prostate cancerMen with non-metastatic castration-resistant prostate cancer (nmCRPC) receiving darolutamide plus androgen deprivation therapy (ADT) had a significant improvement in overall survival (OS) compared to placebo plus ADT (HR=0.69, 95% CI 0.53-0.88; p=0.003) / Darolutamide significantly improved all other secondary endpoints, including time to first initiation of cytotoxic chemotherapy and first symptomatic skeletal event (SSE) / The safety ...
Source: Bayer IR Newsfeed: Events - September 10, 2020 Category: Pharmaceuticals Source Type: news
09.09.20: Not intended for U.S. and UK Media
Bayer completes acquisition of UK-based biotech company KaNDy Therapeutics Ltd.mehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - September 9, 2020 Category: Pharmaceuticals Source Type: news
09.09.20: Bayer collaborates with Recursion to strengthen digital drug discovery and advance new therapies for fibrotic diseases
Bayer collaborates with Recursion to strengthen digital drug discovery and advance new therapies for fibrotic diseasesDrug Discovery partnership and equity investment led by Leaps by Bayer in Series D financing round / Digitally-powered drug discovery to address fibrotic diseases with previously undiscovered mechanisms and to deliver novel therapies to patients fastermehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - September 8, 2020 Category: Pharmaceuticals Source Type: news
08.09.20: Not intended for U.S. and UK Media
Bayer to showcase new data from evolving Oncology portfolio at ESMO Virtual Congress 2020Long-term efficacy and safety results for larotrectinib (Vitrakvi™) from an integrated data set of adult and pediatric patients with TRK fusion cancer, as well as sub-analyses in advanced thyroid and lung cancer patients / Tolerability and treatment response data from the Phase III ARAMIS trial investigating darolutamide (Nubeqa™) in men with non-metastatic castration-resistant prostate cancer (nmCRPC) / Continued research to explore potential of marketed products, evaluating regorafenib (Stivarga™) and radium-223 dic...
Source: Bayer IR Newsfeed: Events - September 8, 2020 Category: Pharmaceuticals Source Type: news
15.09.20: Morgan Stanley Virtual Global Healthcare Conference
Morgan Stanley Virtual Global Healthcare ConferenceLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 28, 2020 Category: Pharmaceuticals Source Type: news
17.09.20: BofA Virtual Global Healthcare Conference
BofA Virtual Global Healthcare ConferenceLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 28, 2020 Category: Pharmaceuticals Source Type: news
